MAPK-Targeted Drug Delivered by a pH-Sensitive MSNP Nanocarrier Synergizes with PD-1 Blockade in Melanoma without T-Cell Suppression

Pseudoprogression and hyperprogression after checkpoint blockade

(2018) Qiaohong Wang et al.   INTERNATIONAL IMMUNOPHARMACOLOGY

Toward Biomaterials for Enhancing Immune Checkpoint Blockade Therapy

(2018) Qin Fan et al.   ADVANCED FUNCTIONAL MATERIALS

Quantification and Stability Determination of Surface Amine Groups on Silica Nanoparticles Using Solution NMR

(2018) Filip Kunc et al.   ANALYTICAL CHEMISTRY

Overviews on the cellular uptake mechanism of polysaccharide colloidal nanoparticles

(2017) Sara Salatin et al.   JOURNAL OF CELLULAR AND MOLECULAR MEDICINE

Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006)

(2017) Jacob Schachter et al.   LANCET

Recurrent Tumor Cell–Intrinsic and –Extrinsic Alterations during MAPKi-Induced Melanoma Regression and Early Adaptation

(2017) Chunying Song et al.   Cancer Discovery

A phase III, randomized, double-blind, multicenter study comparing monotherapy with ipilimumab or gp100 peptide vaccine and the combination in patients with previously treated, unresectable stage III or IV melanoma.

(2017) S. O'Day et al.   JOURNAL OF CLINICAL ONCOLOGY

Combining Immune Checkpoint Inhibitors and Kinase-Inhibiting Supramolecular Therapeutics for Enhanced Anticancer Efficacy

(2016) Ashish Kulkarni et al.   ACS Nano

Irinotecan Delivery by Lipid-Coated Mesoporous Silica Nanoparticles Shows Improved Efficacy and Safety over Liposomes for Pancreatic Cancer

(2016) Xiangsheng Liu et al.   ACS Nano

Functional Group Coverage and Conversion Quantification in Nanostructured Silica by 1H NMR

(2016) Carina I. C. Crucho et al.   ANALYTICAL CHEMISTRY

Genomic and Transcriptomic Features of Response to Anti-PD-1 Therapy in Metastatic Melanoma

(2016) Willy Hugo et al.   CELL

Sequential treatment with immunotherapy and BRAF inhibitors in BRAF-mutant advanced melanoma

(2016) F. Aya et al.   Clinical & Translational Oncology

Expansion of the Gene Ontology knowledgebase and resources

(2016)   NUCLEIC ACIDS RESEARCH

The YUMM lines: a series of congenic mouse melanoma cell lines with defined genetic alterations

(2016) Katrina Meeth et al.   Pigment Cell & Melanoma Research

Dissecting the multicellular ecosystem of metastatic melanoma by single-cell RNA-seq

(2016) I. Tirosh et al.   SCIENCE

Drug-Loaded Mesoporous Tantalum Oxide Nanoparticles for Enhanced Synergetic Chemoradiotherapy with Reduced Systemic Toxicity

(2016) Yuyan Chen et al.   Small

Preparation of pH-responsive mesoporous hydroxyapatite nanoparticles for intracellular controlled release of an anticancer drug

(2016) Dalong Li et al.   Biomaterials Science

Non-genomic and Immune Evolution of Melanoma Acquiring MAPKi Resistance

(2015) Willy Hugo et al.   CELL

The BRAF and MEK Inhibitors Dabrafenib and Trametinib: Effects on Immune Function and in Combination with Immunomodulatory Antibodies Targeting PD-1, PD-L1, and CTLA-4

(2015) L. Liu et al.   CLINICAL CANCER RESEARCH

Co-clinical assessment identifies patterns of BRAF inhibitor resistance in melanoma

(2015) Lawrence N. Kwong et al.   JOURNAL OF CLINICAL INVESTIGATION

Pseudoprogression and Immune-Related Response in Solid Tumors

(2015) Victoria L. Chiou et al.   JOURNAL OF CLINICAL ONCOLOGY

Nanoparticle uptake: The phagocyte problem

(2015) Heather Herd Gustafson et al.   Nano Today

Mesoporous silica nanoparticles in drug delivery and biomedical applications

(2015) Ying Wang et al.   Nanomedicine-Nanotechnology Biology and Medicine

Pembrolizumab versus Ipilimumab in Advanced Melanoma

(2015) Caroline Robert et al.   NEW ENGLAND JOURNAL OF MEDICINE

Severe gastrointestinal toxicity with administration of trametinib in combination with dabrafenib and ipilimumab

(2015) David R. Minor et al.   Pigment Cell & Melanoma Research

From tunable core-shell nanoparticles to plasmonic drawbridges: Active control of nanoparticle optical properties

(2015) C. P. Byers et al.   Science Advances

Outcomes of patients with metastatic melanoma treated with immunotherapy prior to or after BRAF inhibitors

(2014) Allison Ackerman et al.   CANCER

Mesoporous Silica Nanoparticles Coated by Layer-by-Layer Self-assembly Using Cucurbit[7]uril for in Vitro and in Vivo Anticancer Drug Release

(2014) Qing-Lan Li et al.   CHEMISTRY OF MATERIALS

Comparative profile of cutaneous adverse events: BRAF/MEK inhibitor combination therapy versus BRAF monotherapy in melanoma

(2014) Martina Sanlorenzo et al.   JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY

Combined BRAF and MEK Inhibition versus BRAF Inhibition Alone in Melanoma

(2014) Georgina V. Long et al.   NEW ENGLAND JOURNAL OF MEDICINE

MEK Inhibition, Alone or in Combination with BRAF Inhibition, Affects Multiple Functions of Isolated Normal Human Lymphocytes and Dendritic Cells

(2014) L. J. Vella et al.   Cancer Immunology Research

GSVA: gene set variation analysis for microarray and RNA-Seq data

(2013) Sonja Hänzelmann et al.   BMC BIOINFORMATICS

BRAF Inhibition Is Associated with Enhanced Melanoma Antigen Expression and a More Favorable Tumor Microenvironment in Patients with Metastatic Melanoma

(2013) D. T. Frederick et al.   CLINICAL CANCER RESEARCH

Cellular uptake of nanoparticles as determined by particle properties, experimental conditions, and cell type

(2013) Katja Kettler et al.   ENVIRONMENTAL TOXICOLOGY AND CHEMISTRY

A Genome-Scale RNA Interference Screen Implicates NF1 Loss in Resistance to RAF Inhibition

(2013) Steven R. Whittaker et al.   Cancer Discovery

Acquired Resistance and Clonal Evolution in Melanoma during BRAF Inhibitor Therapy

(2013) H. Shi et al.   Cancer Discovery

A pH-responsive polymer/mesoporous silica nano-container linked through an acid cleavable linker for intracellular controlled release and tumor therapy in vivo

(2013) Mian Chen et al.   Journal of Materials Chemistry B

Paradoxical Activation of T Cells via Augmented ERK Signaling Mediated by a RAF Inhibitor

(2013) M. K. Callahan et al.   Cancer Immunology Research

BRAF Inhibitor Vemurafenib Improves the Antitumor Activity of Adoptive Cell Immunotherapy

(2012) Richard C. Koya et al.   CANCER RESEARCH

Mesoporous silicananoparticles: A multifunctional nano therapeutic system

(2012) Wilson X. Mai et al.   Integrative Biology

Combined BRAF and MEK Inhibition in Melanoma with BRAF V600 Mutations

(2012) Keith T. Flaherty et al.   NEW ENGLAND JOURNAL OF MEDICINE

Survival in BRAF V600–Mutant Advanced Melanoma Treated with Vemurafenib

(2012) Jeffrey A. Sosman et al.   NEW ENGLAND JOURNAL OF MEDICINE

RASMutations in Cutaneous Squamous-Cell Carcinomas in Patients Treated with BRAF Inhibitors

(2012) Fei Su et al.   NEW ENGLAND JOURNAL OF MEDICINE

Aspect Ratio Determines the Quantity of Mesoporous Silica Nanoparticle Uptake by a Small GTPase-Dependent Macropinocytosis Mechanism

(2011) Huan Meng et al.   ACS Nano

β-Catenin Signaling Controls Metastasis in Braf-Activated Pten-Deficient Melanomas

(2011) William E. Damsky et al.   CANCER CELL

Combinatorial Treatments That Overcome PDGFR -Driven Resistance of Melanoma Cells to V600EB-RAF Inhibition

(2011) H. Shi et al.   CANCER RESEARCH

Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation

(2011) Paul B. Chapman et al.   NEW ENGLAND JOURNAL OF MEDICINE

Multifunctional Stable and pH-Responsive Polymer Vesicles Formed by Heterofunctional Triblock Copolymer for Targeted Anticancer Drug Delivery and Ultrasensitive MR Imaging

(2010) Xiaoqiang Yang et al.   ACS Nano

The EPR effect: Unique features of tumor blood vessels for drug delivery, factors involved, and limitations and augmentation of the effect

(2010) Jun Fang et al.   ADVANCED DRUG DELIVERY REVIEWS

Selective BRAFV600E Inhibition Enhances T-Cell Recognition of Melanoma without Affecting Lymphocyte Function

(2010) A. Boni et al.   CANCER RESEARCH

Autonomous in Vitro Anticancer Drug Release from Mesoporous Silica Nanoparticles by pH-Sensitive Nanovalves

(2010) Huan Meng et al.   JOURNAL OF THE AMERICAN CHEMICAL SOCIETY

Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation

(2010) Ramin Nazarian et al.   NATURE

Inhibition of Mutated, Activated BRAF in Metastatic Melanoma

(2010) Keith T. Flaherty et al.   NEW ENGLAND JOURNAL OF MEDICINE

Polyethyleneimine Coating Enhances the Cellular Uptake of Mesoporous Silica Nanoparticles and Allows Safe Delivery of siRNA and DNA Constructs

(2009) Tian Xia et al.   ACS Nano

Extracellularly Activated Nanocarriers: A New Paradigm of Tumor Targeted Drug Delivery

(2009) Emily Gullotti et al.   MOLECULAR PHARMACEUTICS

BrafV600E cooperates with Pten loss to induce metastatic melanoma

(2009) David Dankort et al.   NATURE GENETICS

The effect of particle design on cellular internalization pathways

(2008) S. E. A. Gratton et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA